Literature DB >> 19288025

Antiviral effect of arginine against herpes simplex virus type 1.

Takeshi Naito1, Hiroshi Irie, Kazuko Tsujimoto, Keiko Ikeda, Tsutomu Arakawa, A Hajime Koyama.   

Abstract

We investigated the effects of arginine on the multiplication of herpes simplex virus type 1 (HSV-1) and the potential of arginine as an antiherpetic agent. Arginine suppressed the growth of HSV-1 concentration-dependently. Inhibition of HSV-1 by arginine leveled off at 50-60 mM, although the higher concentration was not suitable as an antiviral agent due to cytotoxicity. 'Time of addition' experiments revealed that arginine was particularly effective when added within 6 h post-infection (h p.i.), suggesting that the reagent sensitive step is in the early stages of the infection. A one-step growth curve of HSV-1 in the presence of 30 mM arginine revealed that: i) the latent period was significantly extended, ii) the rate of formation of progeny infectious virus decreased and iii) the final yield of progeny virus decreased to 1%. The addition of arginine at 8 h p.i., after the completion of viral DNA replication in the virus multiplication, allowed the normal formation of progeny virus in the subsequent 4 h, confirming that arginine does not directly interfere with the formation of progeny infectious virus. In addition, arginine also inhibits several RNA viruses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288025     DOI: 10.3892/ijmm_00000156

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  11 in total

1.  Influence of L-lysine amino acid on the HIV-1 RNA replication in vitro.

Authors:  Evgeny Vlad Butorov
Journal:  Antivir Chem Chemother       Date:  2015-02

2.  Novel strategy with acidic arginine solution for the treatment of influenza A virus infection.

Authors:  Keiko Ikeda; Hisashi Yamasaki; Yukiko Suzuki; A Hajime Koyama; Tsutomu Arakawa
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

3.  Antiviral and virucidal activities of nα-cocoyl-L-arginine ethyl ester.

Authors:  Hisashi Yamasaki; Kazuko Tsujimoto; Keiko Ikeda; Yukiko Suzuki; Tsutomu Arakawa; A Hajime Koyama
Journal:  Adv Virol       Date:  2011-11-28

4.  Human Herpesvirus 6A Exhibits Restrictive Propagation with Limited Activation of the Protein Kinase R-eIF2α Stress Pathway.

Authors:  Eyal Sharon; Niza Frenkel
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

5.  A Systems Vaccinology Approach Reveals the Mechanisms of Immunogenic Responses to Hantavax Vaccination in Humans.

Authors:  Adnan Khan; Ok Sarah Shin; Jinhyuk Na; Jae Kwan Kim; Rak-Kyun Seong; Man-Seong Park; Ji Yun Noh; Joon Young Song; Hee Jin Cheong; Youngja Hwang Park; Woo Joo Kim
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

6.  Recurrent Herpes Zoster Ophthalmicus Preceded by Anabolic Steroids and High-Dose L-Arginine.

Authors:  Stephen A LoBue; Adam Goldman; Richard A Giovane; Stacy M Carlson; Michael Bivona; Sinan Albear; Thomas D LoBue
Journal:  Case Rep Ophthalmol Med       Date:  2020-12-28

7.  Relationship between plasma l-lysine concentrations and levels of HIV-1 RNA.

Authors:  Evgeny Vlad Butorov
Journal:  Virulence       Date:  2013-09-17       Impact factor: 5.882

8.  Cleansing effect of acidic L-arginine on human oral biofilm.

Authors:  Ayano Tada; Haruyuki Nakayama-Imaohji; Hisashi Yamasaki; Khaleque Hasibul; Saori Yoneda; Keiko Uchida; Hirofumi Nariya; Motoo Suzuki; Minoru Miyake; Tomomi Kuwahara
Journal:  BMC Oral Health       Date:  2016-03-22       Impact factor: 2.757

9.  Plasma L-Carnitine and L-Lysine Concentrations in HIV-Infected Patients.

Authors:  Evgeny V Butorov
Journal:  Open Biochem J       Date:  2017-12-28

10.  Recurrent herpes zoster ophthalmicus in a young, healthy individual taking high doses of l-Arginine.

Authors:  Stephen A LoBue; Prashant Tailor; Stacy M Carlson; Fukutaro Mano; Richard A Giovane; Erin Schaefer; Thomas D LoBue
Journal:  Am J Ophthalmol Case Rep       Date:  2019-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.